The National Institute of Allergy and Infectious Diseases (NIAID) supports a comprehensive portfolio of contract resources to discover and develop novel therapeutic agents for the prevention and treatment of infections caused by Human Immunodeficiency Virus-1 (HIV-1), AIDS-associated opportunistic pathogens, and other infectious agents. Animal model resources constitute one element of this drug discovery and development program. The purpose of the present project is to provide a resource for evaluating potential therapeutics for HIV-1 infection. Details regarding access by the scientific community are provided at: The contractor is responsible for i) evaluating therapeutic agents, alone and in combination, for efficacy and toxicity in vitro and in the SCID-hu thymus/liver animal model; ii) performing quality assurance/control of the components of the in vitro and in vivo assay systems, to insure reproducible evaluation of candidate therapies; iii) determining optimal routes and schedules of administration; iv) modifying the model system as necessary, to augment its usefulness for evaluating potential HIV-1 therapeutics; and 5) preparing and submitting periodic and interim reports.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
J. David Gladstone Institutes
San Francisco
United States
Zip Code
Favre, David; Stoddart, Cheryl A; Emu, Brinda et al. (2011) HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood 117:2189-99
Xie, Dong; Yao, Cheng; Wang, Li et al. (2010) An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54:191-6
Stoddart, Cheryl A; Keir, Mary E; McCune, Joseph M (2010) IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo. PLoS Pathog 6:e1000766
Stoddart, Cheryl A; Nault, Genevieve; Galkina, Sofiya A et al. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 283:34045-52
Stoddart, Cheryl A; Bales, Cheryl A; Bare, Jennifer C et al. (2007) Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One 2:e655
Stoddart, Cheryl A; Joshi, Pheroze; Sloan, Barbara et al. (2007) Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One 2:e1251